Towers Lab



To see a full list of publications please go to Greg's UCL IRIS page and click the publications tab or Greg's Google Scholar link.

John Walter's artwork graces the cover of the December 2018 issue of Cell Stem Cell


Petrillo C, Thorne LG, Unali G, Schiroli G, Giordano AMS, Piras F, Cuccovillo I, Petit SJ, Ahsan F, Noursadeghi M, Clare S, Genovese P, Gentner B, Naldini L, Towers GJ, Kajaste-Rudnitski A Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell. 2018 Dec 6;23(6):820-832.e9. doi: 10.1016/j.stem.2018.10.008. Epub 2018 Nov 8.

Georgana I, Sumner RP, Towers GJ, Maluquer de Motes C. Virulent poxviruses inhibit DNA sensing by preventing STING activation. J Virol. 2018 Feb 28. pii: JVI.02145-17. doi: 10.1128/JVI.02145-17.

Sumner RP, Thorne LG, Fink DL, Khan H, Milne RS, Towers GJ. Are Evolution and the Intracellular Innate Immune System Key Determinants in HIV Transmission? Front Immunol. 2017 Oct 6;8:1246. doi: 10.3389/fimmu.2017.01246. eCollection 2017.

Mlcochova P, Caswell SJ, Taylor IA, Towers GJ, Gupta RK. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J. 2018 Jan 4;37(1):50-62. doi: 10.15252/embj.201796880. Epub 2017 Oct 30.

Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK. A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. EMBO J. 2017 Mar 1;36(5):604-616. doi: 10.15252/embj.201696025. Epub 2017 Jan 25.

Rasaiyaah et al, Nature 2013. Extended data figure 7: Nuclear translocation of NF-κB and IRF3 after HIV-1 capsid mutant infection in MDM.

David A. Jacques, William A. McEwan, Laura Hilditch, Amanda J. Price, Greg J. Towers, Leo C. James. HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. Nature. 2016 Aug 18;536(7616):349-53

Fletcher AJ, Christensen DE, Nelson C, Tan CP, Schaller T, Lehner PJ, Sundquist WI, Towers GJ. TRIM5α requires Ube2W to anchor Lys63-linked ubiquitin chains and restrict reverse transcription. EMBO J. 2015 Aug 4;34(15):2078-95. doi: 10.15252/embj.201490361

Rasaiyaah, J., C. P. Tan, A. J. Fletcher, A. J. Price, C. Blondeau, L. Hilditch, D. A. Jacques, D. L. Selwood, L. C. James, M. Noursadeghi and G. J. Towers. 2013. HIV-1 evades innate immune recognition through specific co-factor recruitment. Nature (2013) doi:10.1038/nature12769

Blondeau, C., A. Pelchen-Matthews, P. Mlcochova, M. Marsh, R. S. Milne, and G. J. Towers. 2013. Tetherin Restricts Herpes Simplex Virus Type 1 and is Antagonised by Glycoprotein M. J Virol. 2013 Sep 25

Bichel, K., A. J. Price, T. Schaller, G. J. Towers, S. M. Freund, and L. C. James. 2013. HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358. Retrovirology 10:81.

Price, A. J., A. J. Fletcher, T. Schaller, T. Elliot, K. Lee, V. N. Kewalramani, J. Chin, G. J. Towers, and L. C. James. 2012. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS pathogens 8:e1002896

Jaques et al, Nature, 2016. Figure 1 HIV-1 capsid hexamers have a pore at the 6-fold symmetry axis.

Schaller, T., K. E. Ocwieja, J. Rasaiyaah, A. J. Price, T. L. Brady, S. L. Roth, S. Hue, A. J. Fletcher, K. Lee, V. N. Kewalramani, M. Noursadeghi, R. G. Jenner, L. C. James, F. D. Bushman, and G. J. Towers. 2011. HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency. PLoS Pathog 7:e1002439

Hué S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, McLaren S, Pillay D, Futreal A, Garson JA, Pybus OG, Kellam P, Towers GJ. 2010. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 7:111.

Ylinen, L. M., Price, A. J., Rasaiyaah, J., Hue, S., Rose, N. J., Marzetta, F., James, L. C. & Towers, G. J. 2010. Conformational Adaptation of Asian Macaque TRIMCyp Directs Lineage Specific Antiviral Activity. PLoS Pathogens 6: e1001062

Mallery, D. L., W. A. McEwan, S. R. Bidgood, G. J. Towers, C. M. Johnson, and L. C. James. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proceedings of the National Academy of Sciences of the United States of America 107:19985-19990.

Cover of Nature Structural and Molecular Biology referencing Price et al, 2009.

Price, A. J., F. Marzetta, M. Lammers, L. M. J. Ylinen, T. Schaller, S. J. Wilson, G. J. Towers* and L. C. James*. 2009. Active site remodelling switches HIV specificity of antiretroviral TRIMCyp. Nature Struct Mol Biol 16: 1036-42 * Corresponding Authors

Gupta, K. R., S. Hué, T. Schaller, E. Verschoor, D. Pillay and G. J. Towers. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PloS Pathogens 5:e1000443

Wilson, S. J., Webb, B. L. J, Ylinen, L. M. J., Verschoor, E., Heeney, J. L., and G. J. Towers. 2008 Independent evolution of an antiviral TRIMCyp in Rhesus Macaques Proc Natl Acad Sci USA. 105: 35507-62

Keckesova, Z., Ylinen, L. M. J. Towers, G. J. 2004. The human and African green monkey TRIM5a genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 101: 10780-5

Towers, G. J., Hatziioannou, T., Cowan, S., Goff, S. P., Luban, J., and Bieniasz, P. D. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Med 9: 1138-43

Figure 1A from Towers GJ, Retrovirology 2007.

Best, S., Le Tissier, P., Towers, G, Stoye, J. P. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829